MAY 14 2026
AstraZeneca — Fasenra (benralizumab) $AZN
for Hypereosinophilic Syndrome
FDA approved AstraZeneca's Fasenra for adult and pediatric patients aged 12+ with hypereosinophilic syndrome without an identifiable non-hematologic cause.
About
Hypereosinophilic syndrome is a condition where the body produces abnormally high levels of eosinophils, a type of white blood cell, which can damage the heart, nervous system, or bone marrow. Fasenra is an antibody that targets and eliminates eosinophils by binding to a specific receptor on their surface. By reducing eosinophil levels, Fasenra may help prevent the organ damage caused by their overproduction.
Pivotal trial
This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to their prior stable HES...
Source: ClinicalTrials.gov
Also in development
Drug Watch — recent news on Fasenra
- AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too - Fierce Pharma
- FDA Approves AstraZeneca's Fasenra | PharmExec - Pharmaceutical Executive
- FDA approves Fasenra for HES, expanding AstraZeneca’s respiratory portfolio - The Pharma Letter
- Vote now for Fasenra Sacramento Open! - USA Today
- Championship Sunday Standout Stats from the Fasenra Sacramento Open. - PPA Tour